Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib.
Chronic myeloid leukemia
Dasatinib
Lymphoma
Primary effusion lymphoma
Journal
Pathobiology : journal of immunopathology, molecular and cellular biology
ISSN: 1423-0291
Titre abrégé: Pathobiology
Pays: Switzerland
ID NLM: 9007504
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
11
2022
accepted:
28
03
2023
medline:
2
11
2023
pubmed:
31
3
2023
entrez:
30
3
2023
Statut:
ppublish
Résumé
Primary effusion lymphoma (PEL) is a malignant lymphomatous effusion, which by definition is Kaposi sarcoma herpesvirus/human herpesvirus 8-positive. PEL typically occurs in HIV-infected patients but can also occur in HIV-negative individuals, including in organ transplant recipients. Tyrosine kinase inhibitors (TKIs) are currently the standard of care for patients with chronic myeloid leukemia (CML), BCR::ABL1-positive. Although TKIs are extremely effective in treating CML, they alter T-cell function by inhibiting peripheral T-cell migration and altering T-cell trafficking and have been associated with the development of pleural effusions. We report a case of PEL in a young, relatively immunocompetent patient with no history of organ transplant receiving dasatinib for CML, BCR::ABL1-positive. We hypothesize that the loss of T-cell function secondary to TKI therapy (dasatinib) may have resulted in the unchecked cellular proliferation of Kaposi sarcoma herpesvirus (KSHV)-infected cells, leading to the emergence of a PEL. We recommend cytologic investigation and KSHV testing in patients being treated with dasatinib for CML who present with persistent or recurrent effusions.
Identifiants
pubmed: 36996787
pii: 000530429
doi: 10.1159/000530429
pmc: PMC10614567
doi:
Substances chimiques
Dasatinib
RBZ1571X5H
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
356-364Informations de copyright
© 2023 The Author(s). Published by S. Karger AG, Basel.
Références
Leukemia. 2022 Jul;36(7):1720-1748
pubmed: 35732829
Cytopathology. 2020 Nov;31(6):602-606
pubmed: 32681657
J Virol. 1999 Jul;73(7):6136-40
pubmed: 10364372
Am J Surg Pathol. 2013 Feb;37(2):241-9
pubmed: 23282971
Blood. 2008 Feb 1;111(3):1366-77
pubmed: 17962511
Histopathology. 2001 Aug;39(2):163-71
pubmed: 11493333
Mod Pathol. 2022 Oct;35(10):1411-1422
pubmed: 35562413
Hematol Oncol. 2009 Dec;27(4):203-10
pubmed: 19337983
Hematology Am Soc Hematol Educ Program. 2013;2013:103-8
pubmed: 24319170
J Clin Oncol. 2016 Jul 10;34(20):2333-40
pubmed: 27217448
Eur Respir J. 2018 Jan 18;51(1):
pubmed: 29348177
Blood. 2022 Feb 17;139(7):1013-1025
pubmed: 34479367
J Med Case Rep. 2019 Sep 23;13(1):301
pubmed: 31543075
Nature. 1999 Dec 23-30;402(6764):889-94
pubmed: 10622254
Nat Med. 2000 Oct;6(10):1121-7
pubmed: 11017143
Blood. 2005 Mar 15;105(6):2473-9
pubmed: 15572591
J Interferon Cytokine Res. 2011 Nov;31(11):791-801
pubmed: 21767154
Am J Surg Pathol. 2012 Aug;36(8):1129-40
pubmed: 22790853
Leuk Res. 2004 Apr;28(4):333-8
pubmed: 15109530
N Engl J Med. 1995 May 4;332(18):1186-91
pubmed: 7700311
Int J Exp Pathol. 2004 Dec;85(6):305-19
pubmed: 15566428
Front Pharmacol. 2019 Nov 25;10:1340
pubmed: 31824308
Blood. 1989 Feb 15;73(3):792-9
pubmed: 2537119
Am J Surg Pathol. 2018 Dec;42(12):1607-1616
pubmed: 30273194
Biology (Basel). 2021 Feb 14;10(2):
pubmed: 33672947
N Engl J Med. 2003 Mar 13;348(11):994-1004
pubmed: 12637609
BMC Cancer. 2021 Apr 27;21(1):468
pubmed: 33906629
Clin Cancer Res. 2008 Apr 15;14(8):2484-91
pubmed: 18413841
Transpl Infect Dis. 2019 Feb;21(1):e13005
pubmed: 30276937